1999
Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia
Jillella A, Doria R, Khan K, Zelterman D, Ahmad Y, Smith B, Holmes W, Becker P, Roberts K, Rappeport J. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplantation 1999, 23: 1095-1100. PMID: 10382947, DOI: 10.1038/sj.bmt.1701786.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationTotal body irradiationBone marrow transplantationConditioning regimenMarrow transplantationMyeloablative regimenRelapse rateBody irradiationHematologic malignanciesAntileukemic effectGood prognosis diseaseHigh-dose cytosineHost disease (GVHD) prophylaxisShort-course methotrexateEvidence of diseaseOverall relapse rateHigh-dose AraPoor prognosis diseaseKaplan-Meier estimatesActuarial survivalConditioning regimensDisease prophylaxisMyeloablative regimensProspective studyRegimen
1992
Pharmacology of agents used in bone marrow transplant conditioning regimens
Wiebe V, Smith B, DeGregorio M, Rappeport J. Pharmacology of agents used in bone marrow transplant conditioning regimens. Critical Reviews In Oncology/Hematology 1992, 13: 241-270. PMID: 1476655, DOI: 10.1016/1040-8428(92)90092-5.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBone Marrow TransplantationBusulfanCarmustineHematopoiesisHumansImmunosuppressive AgentsMelphalanWhole-Body IrradiationConceptsBone marrow transplantationTotal body irradiationConditioning regimensPharmacology of agentsSingle fraction total body irradiationTransplant conditioning regimensTransplantation conditioning regimensConditioning regimentEffective immunosuppressionTBI regimensBody irradiationMarrow transplantationCurative potentialEngraftment rateDonor histocompatibilityToxicity profilePharmacologic behaviorRegimensAntineoplastic propertiesHematopoietic spaceAntineoplastic activityDisease statesPharmacology
1990
Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Progress In Clinical And Biological Research 1990, 333: 207-15. PMID: 1689852.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, MonoclonalAntigens, CDAntigens, DifferentiationBone MarrowBone Marrow CellsBone Marrow TransplantationCD5 AntigensChildChild, PreschoolCombined Modality TherapyCyclophosphamideCytarabineDrug EvaluationGraft vs Host DiseaseHumansImmunotoxinsLeukemiaMiddle AgedMyelodysplastic SyndromesRicinRisk FactorsT-LymphocytesWhole-Body Irradiation
1984
Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation.
Parkman R, Rappeport JM, Hellman S, Lipton J, Smith B, Geha R, Nathan DG. Busulfan and total body irradiation as antihematopoietic stem cell agents in the preparation of patients with congenital bone marrow disorders for allogenic bone marrow transplantation. Blood 1984, 64: 852-7. PMID: 6383499, DOI: 10.1182/blood.v64.4.852.bloodjournal644852.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBone Marrow DiseasesBone Marrow TransplantationBusulfanChildChild, PreschoolFemaleHematopoiesisHistocompatibilityHumansInfantMaleWhole-Body IrradiationConceptsTotal body irradiationBone marrow transplantationBone marrow disordersBody irradiationPreparation of patientsMarrow transplantationMarrow disordersInterstitial pneumonitisAllogeneic bone marrow transplantationAllogenic bone marrow transplantationIdiopathic interstitial pneumonitisCell agentsPreparatory regimenBusulfanPatientsHematopoietic stem cellsTransplantationTransplantPneumonitisDisordersHematopoietic ablationStem cellsRegimenRegimensAgents